HomeCompareHFC vs PFE

HFC vs PFE: Dividend Comparison 2026

HFC yields 60.88% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $19.0K in total portfolio value· pulled ahead in Year 10
10 years
HFC
HFC
● Live price
60.88%
Share price
$36.39
Annual div
$22.15
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.1K
Annual income
$9.69
Full HFC calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — HFC vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHFCPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HFC + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HFC pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HFC
Annual income on $10K today (after 15% tax)
$5,174.38/yr
After 10yr DRIP, annual income (after tax)
$8.24/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $23,120.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HFC + PFE for your $10,000?

HFC: 50%PFE: 50%
100% PFE50/50100% HFC
Portfolio after 10yr
$41.6K
Annual income
$13,610.12/yr
Blended yield
32.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

HFC
No analyst data
Price Target
$36.67
+0.8% upside vs current
Range: $31.00 — $44.00
Altman Z
2.9
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HFC buys
0
PFE buys
0
No recent congressional trades found for HFC or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHFCPFE
Forward yield60.88%6.20%
Annual dividend / share$22.15$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$32.1K$51.1K
Annual income after 10y$9.69$27,210.54
Total dividends collected$7.3K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst price target$36.67$27.50

Year-by-year: HFC vs PFE ($10,000, DRIP)

YearHFC PortfolioHFC Income/yrPFE PortfolioPFE Income/yrGap
1$13,744$3,043.76$9,161$701.38+$4.6KHFC
2$16,661$1,954.80$8,610$859.79+$8.1KHFC
3$18,934$1,107.32$8,366$1,081.25+$10.6KHFC
4$20,848$588.05$8,483$1,405.66+$12.4KHFC
5$22,610$302.56$9,084$1,907.24+$13.5KHFC
6$24,346$153.33$10,418$2,732.78+$13.9KHFC
7$26,127$77.15$13,007$4,193.56+$13.1KHFC
8$27,994$38.69$18,010$7,005.87+$10.0KHFC
9$29,973$19.37$28,216$12,979.89+$1.8KHFC
10← crossover$32,081$9.69$51,081$27,210.54$19.0KPFE

HFC vs PFE: Complete Analysis 2026

HFCStock

HollyFrontier Corporation operates as an independent petroleum refiner and marketer in the United States. The company operates through three segments: Refining, Lubricants and Specialty Products, and HEP. It primarily produces high-value light products, such as gasoline, diesel and jet fuel, and specialty lubricant products, as well as specialty and modified asphalt. The company offers its products to other refiners, convenience store chains, independent marketers, liquid petroleum gases and other retailers, truck stop chains, wholesalers, railroads, governmental entities, and paving contractors or manufacturers, as well as for commercial airline use. It owns and operates five refineries with a combined crude oil processing capacity of approximately 554,000 barrels per day in El Dorado, Kansas; Tulsa, Oklahoma; Anacortes, Washington; Artesia, New Mexico; and Woods Cross, Utah. The company also owns and operates vacuum distillation and other facilities in Lovington, New Mexico, as well as asphalt terminals in Arizona, New Mexico, and Oklahoma. Its refineries serve markets in the Mid-Continent, Southwest, and Rocky Mountain regions of the United States. In addition, the company produces base oils and other specialized lubricant products; and owns and operates logistic assets consisting of petroleum product and crude oil pipelines, terminals, tankage, loading rack facilities, and refinery processing units. The company was formerly known as Holly Corporation and changed its name to HollyFrontier Corporation as a result of its merger with Frontier Oil Corporation in July 2011. HollyFrontier Corporation was incorporated in 1947 and is headquartered in Dallas, Texas.

Full HFC Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this HFC vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HFC vs SCHDHFC vs JEPIHFC vs OHFC vs KOHFC vs MAINHFC vs JNJHFC vs MRKHFC vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.